CN101627056B - Y型聚乙二醇修饰的g-csf及其制备方法和应用 - Google Patents

Y型聚乙二醇修饰的g-csf及其制备方法和应用 Download PDF

Info

Publication number
CN101627056B
CN101627056B CN2007800513782A CN200780051378A CN101627056B CN 101627056 B CN101627056 B CN 101627056B CN 2007800513782 A CN2007800513782 A CN 2007800513782A CN 200780051378 A CN200780051378 A CN 200780051378A CN 101627056 B CN101627056 B CN 101627056B
Authority
CN
China
Prior art keywords
csf
ypeg
pegylated
type
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800513782A
Other languages
English (en)
Chinese (zh)
Other versions
CN101627056A (zh
Inventor
王世媛
郑建华
孙黎
蔡慧丽
杨美花
何艳
陈萍
邓洪渊
钟丽萍
黄淑莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XIAMEN BOSAI GENETIC TRANSCRIPTION TECHNOLOGY Co Ltd
Original Assignee
XIAMEN BOSAI GENETIC TRANSCRIPTION TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XIAMEN BOSAI GENETIC TRANSCRIPTION TECHNOLOGY Co Ltd filed Critical XIAMEN BOSAI GENETIC TRANSCRIPTION TECHNOLOGY Co Ltd
Publication of CN101627056A publication Critical patent/CN101627056A/zh
Application granted granted Critical
Publication of CN101627056B publication Critical patent/CN101627056B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN2007800513782A 2007-12-29 2007-12-29 Y型聚乙二醇修饰的g-csf及其制备方法和应用 Active CN101627056B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/003897 WO2009086656A1 (zh) 2007-12-29 2007-12-29 Y型聚乙二醇修饰的g-csf及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN101627056A CN101627056A (zh) 2010-01-13
CN101627056B true CN101627056B (zh) 2013-05-15

Family

ID=40852740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800513782A Active CN101627056B (zh) 2007-12-29 2007-12-29 Y型聚乙二醇修饰的g-csf及其制备方法和应用

Country Status (8)

Country Link
US (1) US8530417B2 (enExample)
EP (1) EP2236521A4 (enExample)
JP (1) JP2011507913A (enExample)
CN (1) CN101627056B (enExample)
AU (1) AU2007363326B2 (enExample)
BR (1) BRPI0722341A2 (enExample)
CA (1) CA2710841C (enExample)
WO (1) WO2009086656A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710841C (en) 2007-12-29 2018-01-23 Biosteed Gene Expression Tech. Co., Ltd. Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
PT2272875E (pt) * 2008-04-03 2014-04-28 Biosteed Gene Expression Tech Co Ltd Hormona de crescimento modificada com polietilenoglicol de cadeia dupla, método de preparação e aplicação deste
US20120226774A1 (en) 2011-02-23 2012-09-06 Apple Inc. Display snooping
US10849794B2 (en) * 2012-03-01 2020-12-01 Alcare Co., Ltd. Wound dressing
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
CN106146325B (zh) * 2015-04-24 2019-01-29 北京键凯科技股份有限公司 一种y型多缩乙二醇衍生物及其制备方法
CN107446908A (zh) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法
CN108525002B (zh) * 2017-03-01 2020-09-29 中国科学院化学研究所 一种具有高强粘附性能的可注射生物胶水及其制备方法与应用
CN114853872B (zh) * 2022-04-27 2023-11-17 山东新时代药业有限公司 一种聚乙二醇修饰rhG-CSF的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243997C (zh) * 2002-02-25 2006-03-01 协荣线材株式会社 光纤复合套管
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395254C (en) * 1999-12-24 2010-05-11 Kyowa Hakko Kogyo Co., Ltd. Branched polyalkylene glycols
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
JP4873818B2 (ja) * 2000-05-16 2012-02-08 ボルダー バイオテクノロジー， インコーポレイテッド 遊離システイン残基を含有するタンパク質をリフォールディングする方法
WO2003076490A1 (en) * 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
CN1778821A (zh) 2004-10-15 2006-05-31 北京凯正生物工程发展有限责任公司 化学修饰的粒细胞集落刺激因子偶联物及其制备方法
WO2007019331A2 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
CA2710841C (en) 2007-12-29 2018-01-23 Biosteed Gene Expression Tech. Co., Ltd. Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
WO2012064867A1 (en) * 2010-11-09 2012-05-18 Nektar Therapeutics Pharmacologically active polymer-g-csf conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243997C (zh) * 2002-02-25 2006-03-01 协荣线材株式会社 光纤复合套管
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation

Also Published As

Publication number Publication date
CA2710841C (en) 2018-01-23
CN101627056A (zh) 2010-01-13
AU2007363326B2 (en) 2014-01-30
EP2236521A1 (en) 2010-10-06
JP2011507913A (ja) 2011-03-10
BRPI0722341A2 (pt) 2014-03-18
US8530417B2 (en) 2013-09-10
EP2236521A4 (en) 2013-07-10
WO2009086656A1 (zh) 2009-07-16
CA2710841A1 (en) 2009-07-16
AU2007363326A1 (en) 2009-07-16
US20110280826A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
CN101627056B (zh) Y型聚乙二醇修饰的g-csf及其制备方法和应用
JP5336372B2 (ja) Ｇ−ｃｓｆ部位特異的モノコンジュゲート
KR100773323B1 (ko) 지-씨에스에프 접합체
KR100961859B1 (ko) 지-씨에스에프 접합체
US8901277B2 (en) Interferon alpha mutant and its polyethylene glycol derivative
CA2978330C (en) Conjugates of an il-7 moiety and a polymer
Wu et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone
JP2003155299A (ja) Ｎ末端化学修飾タンパク質組成物および方法
RS20050263A (sr) Polimerni konjugati smanjene antigenosti, postupci za njihovo dobijanje i korišćenje
SK9872000A3 (en) Erythropoietin conjugate
CN101389354A (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
JP2007533665A (ja) 新規ｇ−ｃｓｆ結合体
WO2006094530A1 (en) Di-polymer protein conjugates and processes for their preparation
CN115721730B (zh) 聚乙二醇化血管内皮抑制素类似物及其应用
KR101483814B1 (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
JP5458416B2 (ja) 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
WO2011041376A1 (en) Modified granulocyte colony stimulating factor (g-csf)
CN101163716B (zh) 白细胞介素-6聚乙二醇结合物及其制备方法和应用
CN106749608B (zh) 干扰素α缀合物
US20040204566A1 (en) Chemically-modified G-CSF

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant